Sehlikoğlu Şeyma, Yıldız Sevler, Kazğan Kılıçaslan Aslı, Kurt Osman, Göçüm Erkan, Han Almiş Behice
Department of Psychiatry, Adıyaman University, Faculty of Medicine, Adıyaman, Türkiye.
Clinic of Psychiatry, Elazığ City Hospital, Elazığ, Türkiye.
Psychiatry Clin Psychopharmacol. 2024 Jun 1;34(2):134-143. doi: 10.5152/pcp.2024.23803. eCollection 2024 Jun.
The aim of this study was to compare the complete blood cell count parameters of patients with methamphetamine and synthetic cannabis use disorder (MCUD), a condition that has recently exhibited a gradual increase in prevalence, with those of healthy subjects.
In total, 76 patients diagnosed with MCUD and 78 healthy controls were included in the study. Venous blood samples were collected from all participants at presentation for laboratory examination.
The rate of mono- and poly-substance users in the patient group was 14.5% and 85.5%, respectively. The average duration of methamphetamine (METH) use in the patient group is 3.0 ± 1.9 years. White blood cell ( < .001), PLT ( = .005), monocyte count ( < .001), basophil count ( < .001), neutrophil count ( < .001), lymphocyte count ( < .001) basophil/lymphocyte ratio (BLR) ( = .04), SII ( = .006), and SIRI ( = .001) values were significantly higher. In contrast Hgb ( = .043), Hct ( = .002), monocyte percentage ( = .004), and RBC ( = .021) values were significantly lower in the MCUD group compared to the control group. There was a significant positive correlation between neutrophil/lymphocyte ratio and platelet/lymphocyte ratio ( = .552 < .001) and between systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) ( = 0.580 < .001).
Methamphetamine and cannabis may affect the levels of inflammatory markers and SII and SIRI values through various mechanisms. To the best of our knowledge, this is the first study in the relevant literature, which investigated SII and SIRI values in patients with MCUD, therefore, the results can contribute to the future development of immune system-related markers in this field.
本研究旨在比较甲基苯丙胺和合成大麻使用障碍(MCUD)患者(这种疾病的患病率最近呈逐渐上升趋势)与健康受试者的全血细胞计数参数。
本研究共纳入76例诊断为MCUD的患者和78例健康对照。在所有参与者就诊时采集静脉血样本进行实验室检查。
患者组中单物质和多物质使用者的比例分别为14.5%和85.5%。患者组中甲基苯丙胺(METH)的平均使用时长为3.0±1.9年。白细胞(<0.001)、血小板(=0.005)、单核细胞计数(<0.001)、嗜碱性粒细胞计数(<0.001)、中性粒细胞计数(<0.001)、淋巴细胞计数(<0.001)、嗜碱性粒细胞/淋巴细胞比值(BLR)(=0.04)、全身免疫炎症指数(SII)(=0.006)和全身炎症反应指数(SIRI)(=0.001)值显著更高。相比之下,MCUD组的血红蛋白(=0.043)、血细胞比容(=0.002)、单核细胞百分比(=0.004)和红细胞(=0.021)值显著低于对照组。中性粒细胞/淋巴细胞比值与血小板/淋巴细胞比值之间(=0.552,<0.001)以及全身免疫炎症指数(SII)与全身炎症反应指数(SIRI)之间(=0.580,<0.001)存在显著正相关。
甲基苯丙胺和大麻可能通过多种机制影响炎症标志物水平以及SII和SIRI值。据我们所知,这是相关文献中第一项研究MCUD患者SII和SIRI值的研究,因此,研究结果有助于该领域免疫系统相关标志物的未来发展。